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Abstract
Background: Betacellulin (BTC), a member of the epidermal growth factor family, is known to play an important role in
regulating growth and differentiation of pancreatic beta cells. Growth-promoting actions of BTC are mediated by epidermal
growth factor receptors (ErbBs), namely ErbB-1, ErbB-2, ErbB-3 and ErbB-4; however, the exact mechanism for beta cell
proliferation has not been elucidated. Therefore, we investigated which ErbBs are involved and some molecular
mechanisms by which BTC regulates beta cell proliferation.
Methodology/Principal Findings: The expression of ErbB-1, ErbB-2, ErbB-3, and ErbB-4 mRNA was detected by RT-PCR in
both a beta cell line (MIN-6 cells) and C57BL/6 mouse islets. Immunoprecipitation and western blotting analysis showed that
BTC treatment of MIN-6 cells induced phosphorylation of only ErbB-1 and ErbB-2 among the four EGF receptors. BTC
treatment resulted in DNA synthetic activity, cell cycle progression, and bromodeoxyuridine (BrdU)-positive staining. The
proliferative effect was blocked by treatment with AG1478 or AG825, specific tyrosine kinase inhibitors of ErbB-1 and ErbB-2,
respectively. BTC treatment increased mRNA and protein levels of insulin receptor substrate-2 (IRS-2), and this was blocked
by the ErbB-1 and ErbB-2 inhibitors. Inhibition of IRS-2 by siRNA blocked cell cycle progression induced by BTC treatment.
Streptozotocin-induced diabetic mice injected with a recombinant adenovirus expressing BTC and treated with AG1478 or
AG825 showed reduced islet size, reduced numbers of BrdU-positive cells in the islets, and did not attain BTC-mediated
remission of diabetes.
Conclusions/Significance: These results suggest that BTC exerts proliferative activity on beta cells through the activation of
ErbB-1 and ErbB-2 receptors, which may increase IRS-2 expression, contributing to the regeneration of beta cells.
Citation: Oh YS, Shin S, Lee Y-J, Kim EH, Jun H-S (2011) Betacellulin-Induced Beta Cell Proliferation and Regeneration Is Mediated by Activation of ErbB-1 and
ErbB-2 Receptors. PLoS ONE 6(8): e23894. doi:10.1371/journal.pone.0023894
Editor: Kathrin Maedler, University of Bremen, Germany
Received January 26, 2011; Accepted July 27, 2011; Published August 29, 2011
Copyright:  2011 Oh et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the grants from National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (NO. 2009-
0079342). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: hsjeon@gachon.ac.kr
Introduction
Islet transplantation is currently the most promising treatment
for type 1 diabetes, but there are side effects associated with the
immunosuppressive agents and limitations resulting from a shortage
of pancreas donors [1]. Therefore, generation of new beta cells
either in vitro or in vivo is a high priority issue in diabetes treatment,
and the identification of factors regulating the expansion of insulin-
producing cells has potential importance for the treatment of
diabetes.
Betacellulin (BTC), a member of the epidermal growth factor
(EGF) family, was originally identified as a growth-promoting
factor in the conditioned medium of a mouse pancreatic beta cell
carcinoma (insulinoma) cell line [2]. BTC is proteolytically pro-
cessed from a larger membrane-anchored 178-aminio acid pre-
cursor, and mature BTC is a 32-kDa glycoprotein of 80 amino
acid [3]. BTC is synthesized in a wide range of tissues in the adult
body and in a large number of cultured cells, including smooth
muscle cells and epithelial cells. BTC mRNA is particularly highly
expressed in the pancreas, liver, kidney and small intestine [4,5].
In the pancreas, high expression of BTC mRNA suggests that
BTC may have physiological role in the development and function
of pancreas. Indeed, BTC is known to induce proliferation and
differentiation of endocrine precursor cells in the pancreas. BTC,
together with activin-A, can convert populations of exocrine
AR42J rat pancreatic acinar cells into insulin-secreting cells [6]
and mediate the proliferation of a fetal pancreatic epithelial cell
line [7] as well as a rat insulinoma cell line [8]. Administration of a
recombinant adenoviral vector expressing BTC (rAd-BTC) into
streptozotocin (STZ)-induced diabetic mice restores normoglyce-
mia [9]. As well, either ubiquitous [10] or beta cell-specific [11]
BTC overexpression improves glucose metabolism in mice.
The effects of BTC are mediated by binding to one or more of
four receptors in the tyrosine kinase family: ErbB-1/EGFR, ErbB-
2/HER2/neu, ErbB-3, and ErbB-4/HER4 [3,12]. BTC was
found to bind all possible combinations of heterodimeric ErbB
receptor as well as ErbB-1 and ErbB-4 homodimers, based on
results using cell lines engineered to ectopically express pairwise
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ligand, tyrosine residues on the ErbB receptors become phosphor-
ylated followed by secondary messenger recruitment. The Ras- and
Shc-activated mitogen-activated protein kinase (MAPK) pathway
and the phosphoinositide 3-kinase (PI3K)-activated Akt pathway
are the most important signaling networks of most ErbBs [13].
These receptor signaling pathways are critical for cell proliferation,
migration, differentiation, cancer progression and apoptosis [14].
To understand the biological role of ErbB receptors on the
pancreas, transgenic mouse models have been established and their
phenotypes characterized, but most ErbB receptor-deficient mice
die at embryonic day 10.5–13.5 and development of the islets is
impaired [15–17]. These results indicate that ErbB receptors play
an important role in the development of the pancreas.
Various transcription factors, forkhead box transcription factor
O1, hypoxia-inducible factor-1a, and cAMP response element
binding protein (CREB), have been implicated in BTC-mediated
proliferation [18–20] and induce transcription of genes such as
pancreatic and duodenal homeobox-1 and insulin receptor sub-
strate (IRS)-2, which are known to be involved in beta cell
proliferation [21,22]. In this study, we investigated which ErbBs
are involved in BTC-induced proliferation and regeneration of
pancreatic beta cells and the mechanisms involved. We found that
BTC activates ErbB-1 and ErbB-2 and consequently induces IRS-
2 expression, contributing to beta cell proliferation and BTC-
mediated beta cell regeneration in diabetic mice.
Results
Proliferative effect of BTC on beta cells
TotesttheproliferativeeffectofBTC,abetacellline(MIN-6cells)
was treated with various concentrations of BTC for 24 h and the cell
viability was analyzed. We found that 0.5 nM of BTC (Fig. 1A) and
incubation for 24 h (Fig. 1B) was optimal for the proliferative effects
of BTC. To confirm the mitogenic effects, thymidine incorpora-
tion was measured at 24 h after stimulation with 0.5 nM BTC.
Thymidine incorporation over 4 h was significantly increased in
BTC-treated MIN-6 cells as compared with untreated cells (100% vs
118%, p,0.01) (Fig. 1C). The proportion of cells progressing to S
phase, as analyzed by propidium iodide staining, was also higher in
BTC-treated cells as compared with untreated cells (100% vs 120%,
p,0.05) (Fig. 1D). 5-bromodexoyuridine (BrdU) incorporation into
MIN-6 cells by BTC treatment, evidenced by an increase of insulin
andBrdUdouble-stainedcellsasapercentageofinsulin-positivecells
(0.33% vs 0.81%, p,0.05), also confirmed the proliferative effect of
BTC (Fig. 1E).
Activation of ErbB-1 and ErbB-2 by BTC treatment in beta
cells
BecauseBTCexertsbiologicaleffectsthroughErbBreceptors,we
first examined the distribution of subtypes of ErbB receptors in islets
isolated from C57BL/6 mice and in MIN-6 cells. RT-PCR analyses
revealed that both MIN-6 cells and mouse islets express all four
ErbB receptors, although ErbB-2 expression levels were lower than
the other ErbBs (Fig. 2A). Next, we checked which EGF receptors
were activated by BTC treatment. Cells were prepared after 0, 1, 5,
or 15 min of incubation with BTC (0.5 nM), and phosphorylated
ErbBs were examined by immunoprecipitation and western blot. As
shown in Fig. 2B, phosphorylated ErbBs were barely detected in the
absence of BTC treatment. Following addition of BTC, a striking
increase in ErbB-1 and -2 phosphorylation was detected within
1 min, indicating that these two receptors were being activated by
the BTC ligand. However, phosphorylation of ErbB-3 and ErbB-4
was not detected after BTC treatment.
Inhibition of BTC-induced beta cell proliferation by ErbB-
1 and ErbB-2 inhibitors
As we found that ErbB-1 and ErbB-2 were phosphorylated by
BTC treatment, we examined whether inhibition of tyrosine
phosphorylation of ErbB-1 and ErbB-2 would affect BTC-induced
proliferation of beta cells. MIN-6 cells were stimulated with BTC
(0.5 nM) for 24 h in the presence of 4 nM of AG1478 or AG825.
AG1478 is known as a potent and selective inhibitor of ErbB-1
(IC50=3 nM), but does not inhibit ErbB-2 (IC50.100 mM) [23],
and AG825 is a specific inhibitor of ErbB-2 [24]. Treatment of the
cells with either inhibitor significantly suppressed BTC-induced
DNA synthesis (Fig. 3A) and progression of G1 to S phase (Fig. 3B).
These results suggest that the proliferative effect of BTC is
mediated through ErbB-1 and ErbB-2 receptors.
Inhibition of BTC-induced IRS-2 expression by ErbB-1 and
ErbB-2 inhibitors
Because IRS-2 is known to play a crucial role in beta cell
survival and growth [25,26], we investigated whether BTC
regulates IRS-2 expression levels. We first tested effects of BTC
on the expression of IRS-2 mRNA or protein. Treatment of MIN-
6 cells with 0.5 nM of BTC significantly upregulated IRS-2
mRNA levels at 2 h of treatment (Fig. 4A). Protein levels of IRS-2
were also increased after 6 and 12 h of BTC treatment compared
with the control (Fig. 4B). To determine whether inhibition of
IRS-2 blocks the effect of BTC, we transfected cells with IRS-2
small interfering (si) RNA or a control siRNA and treated them
with BTC. We found that IRS-2 expression (Fig. 4C) and the
proportion of cells in S phase (109% vs 88%, p,0.05) (Fig. 4D) was
significantly reduced in IRS-2 siRNA-transfected cells as com-
pared with control siRNA-transfected cells. Next, we examined the
effect of ErbB-1 and ErbB-2 inhibitors on IRS-2 expression, and
found that treatment with AG1478 or AG825 completely blocked
BTC-induced IRS-2 mRNA expression (Fig. 4E).
Involvement of ErbB-1 and ErbB-2 receptors in BTC-
induced regeneration in vivo
Previously, we observed that administration of a recombinant
adenovirus expressing BTC (rAd-BTC) into streptozotocin (STZ)-
induced NOD.SCID diabetic mice resulted in remission of
hyperglycemia by regeneration of beta cells [9]. Since we found that
ErbB-1 and ErbB-2 receptors are involved in BTC-mediated
proliferation in MIN-6 cells, we investigated whether these receptors
are involved in regeneration of pancreatic beta cells by BTC in vivo.
We first checked the expression of ErbBs by immunohistochemical
staining with anti-ErbB-1 and ErbB-2 antibodies in the pancreatic
islets of normal mice, STZ-induced diabetic NOD.SCID mice, and
STZ-induced diabetic NOD.SCID mice treated with rAd-BTC.
Expression of ErbB-1 and ErbB-2 was detected in islets from STZ-
induced diabetic mice and STZ-induced diabetic mice treated with
rAd-BTC, but was barely detected in islets from normal mice.
Interestingly, the upregulation of ErbB-2 expression appeared to be
greater than the upregulation of ErbB-1 expression in the islets of
diabetic mice (Fig. 5A).
Next, to examine whether ErbB-1 and ErbB-2 receptors are
involved inBTC-induced remission of diabetes, we injectedAG1478
or AG825 for 10 days into STZ-induced diabetic NOD.SCID mice
treated with rAd-BTC beginning on the third day after virus
injection and measured blood glucoselevels. We found that injection
of AG825 abrogated the remission of diabetes by rAd-BTC.
However, when AG825 injections were stopped on the thirteenth
day after virus injection, blood glucose levels gradually decreased
and becamenormoglycemic(about100 mg/dl)at23 daysafter virus
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PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e23894Figure 1. Proliferative effect of BTC on beta cells. The number of viable MIN-6 cells was determined after incubation with (A) various
concentrations of BTC for 24 h or (B) 0.5 nM of BTC for various times. Relative cell numbers are expressed as fold changes over control levels (CON).
(C) MIN-6 cells were incubated with 0.5 nM of BTC for 24 hrs and a
3H-thymidine incorporation assay was performed. The data are presented as the
percent of untreated cells (CON). (D) Cells were harvested by trypsinization, stained with propidium iodide, and analyzed by flow cytometry. Values
are percent of cells in S phase relative to that of untreated cells (CON). (E) MIN-6 cells were incubated without (CON) and with BTC (0.5 nM). Cells
were fixed with paraformaldehyde and stained with DAPI (nucleus marker) and anti-insulin (INS) and anti-BrdU (BrdU) antibodies. The arrows show
cells positive for insulin and BrdU. Proliferation of insulin-positive cells is shown as the number of BrdU/insulin double-positive cells as a percentage
of the total number of insulin-positive cells (right panel). Values are means 6 SEM of three experiments. Scale bar=20 mm.*p,0.05, **p,0.01 vs
CON.
doi:10.1371/journal.pone.0023894.g001
ErbBs on BTC-Induced Beta Cell Proliferation
PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e23894injection. The effect of AG1478 on the abrogation of BTC-induced
remission of diabetes was less pronounced than that of AG825
(Fig. 5B). Islet size was significantly reduced in AG1478- or AG825-
treated mice compared with mice injected with rAd-BTC alone
(Fig. 5C).
To examine whether the decreased islet size in AG1478- or
AG825-treated mice was caused by reduced beta cell proliferation,
we injected rAd-BTC and inhibitors with BrdU, which labels
dividing cells, for 5 days beginning on day 1 after rAd-BTC
injection and stained pancreatic sections with anti-BrdU and anti-
insulin antibodies. We found that double-stained cells were highly
increased in islets of rAd-BTC-treated mice compared with normal
mice, but the number of double-stained cells was significantly
decreased by AG1478 or AG825 treatment (Fig. 5D, E).
Discussion
The pancreatic beta cell mass is dynamic and can increase when
exposed to appropriate environmental and physiological changes,
such as obesity and pregnancy [27], and growth stimuli such as
BTC, glucagon-like peptide-1 [28] and gastrin [29]. As diabetes
results from absolute or relative deficiency of the beta cell mass,
restoration of the beta cell mass might be one strategy for the
treatment of diabetes. For this, various methods have been
Figure 2. Expression of ErbBs and phosphorylation of ErbBs in MIN-6 cells treated with BTC. (A) mRNA expression of ErbBs in MIN-6 cells
(MIN6) and isolated C57BL/6 mouse islets (islet) were determined by RT-PCR using specific primers. GAPDH was used as a loading control. (B) MIN-6
cells were incubated with BTC for the indicated times. Cell lysate was immunoprecipited (IP) with anti-ErbB antibodies and phosphorylated ErbBs
were then detected by western blot (WB) using phospho-specific antibodies (Phospho-Tyr).
doi:10.1371/journal.pone.0023894.g002
Figure 3. Inhibition of BTC-induced beta cell proliferation by ErbB-1 and ErbB-2 inhibitors. MIN-6 cells were incubated with BTC (0.5 nM)
for 24 h with or without inhibitors AG1478 or AG825. (A)
3H-thymidine incorporation assay was performed. The data are presented as the percent of
control (CON). (B) Cells were harvested by trypsinization, stained with propidium iodide, and analyzed by flow cytometry. Values are percent of cells
in S phase relative to that of untreated cells (CON). Values are means 6 SEM of three experiments, **p,0.01 vs BTC.
doi:10.1371/journal.pone.0023894.g003
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from progenitor/stem cells and regeneration of beta cells.
We previously found that in vivo BTC expression by delivery of a
recombinant adenovirus expressing BTC (rAd-BTC) remitted
hyperglycemia in STZ-induced diabetic mice by beta cell regen-
eration [9], and some studies showed that new beta cells by BTC
are generated mainly by replication of pre-existing beta cells
[9,30]. BTC is a potent growth factor that has positive effects on
beta cell growth, through both increased proliferation and
neogenesis. BTC promotes beta cell neogenesis from the pancreatic
duct, therefore improving glycemic control after selective beta cell
destruction with alloxan or after 90% pancreatectomy [31,32]. In
addition to BTC, other EGF receptor ligands have positive effects
on beta cells. For example, EGF alone or combination with gastrin
increased insulin secretion and beta cell numbers [33], and EGF
treatment increased serum insulin levels and lowered blood glucose
levelsindiabetic mice[34].Transforminggrowthfactor-a increased
beta cell growth and differentiation [35], and epiregulin, another
EGF receptor ligand, stimulated beta cell proliferation and insulin
release in pancreatic beta cell lines [36]. The functional redundancies
Figure 4. Inhibition of BTC-induced IRS-2 expression in beta cells. MIN-6 cells were incubated with BTC (0.5 nM) for the indicated times. (A)
Total RNA was isolated and quantitative real-time PCR for IRS-2 mRNA was performed. (B) Total protein was isolated, and immunoblotting was done
for IRS-2 or actin. (C) MIN-6 cells were transfected with IRS-2 siRNA or control (Con) siRNA. After 48 h, cells were harvested and mRNA expression of
IRS-2 was analyzed by quantitative real-time PCR using IRS-2 primers. (D) After transfection with IRS-2-specific siRNA for 48 h, cells were treated with
BTC for 24 h. Cells were harvested, stained with propidium iodide, and analyzed by flow cytometry. Values are percent of cells in S phase relative to
that of untreated cells (CON). (E) MIN-6 cells were treated with 0.5 nM BTC in the presence or absence of ErbB inhibitors (4 nM) for 2 h. Total RNA was
isolated and qRT-PCR for IRS-2 mRNA was performed. Values are means 6 SEM of three experiments, *p,0.05.
doi:10.1371/journal.pone.0023894.g004
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ligands via a conserved motif might be important mediators of beta
cell mass regulation.
Because BTC produces physiological and pathological effects
through its ErbB receptors, their distribution and activation are
crucial for the function of BTC. It was reported that proliferative
responses after BTC treatment were different between INS-1 cells
and more primitive RINm5F cells, due to differential expression of
ErbB family receptors [8]. Moreover, a BTC mutant protein, with
a single mutation replacing glutamic acid with lysine, changed the
binding affinity to ErbB receptors and resulted the differentiation
of AR42J cells into insulin-secreting cells [37]. These studies
indicate that the expression and affinity or activity of ErbBs play
important roles for BTC function.
Sundaresan et al. reported that the ability of cells to respond to
ligand is dependent on the expression of specific ErbB receptor
combinations in the target tissue [7]. To investigate which ErbBs
are involved in BTC-induced beta cell proliferation, we first
checked the expression of ErbBs in MIN-6 insulinoma cells and
mouse islets and observed that all known ErbB isoforms (ErbB-1,
ErbB-2, ErbB-3, ErbB-4) were expressed both in MIN-6 cells and
islets of C57BL/6 mice. Expression of four types of ErbB receptors
in the MIN-6 cells suggests that multiple combinations of receptor
heterodimers are able to form. However, we found that BTC
induced only ErbB-1 and ErbB-2 phosphorylation in MIN-6 cells,
suggesting that BTC may bind ErbB-1 and ErbB-2 in beta cells
and deliver the signals for biological actions. Because it was
reported that homodimers of ErbB-2 or ErbB-3 cannot mediate
the growth factor signal and they form heterodimers with ErbB-1
and ErbB-4 [3], our results suggest that BTC-induced beta cell
proliferation could occur through activation of ErbB-1 homodi-
mers or ErbB-1/ErbB-2 heterodimer. As expected, BTC-induced
DNA synthesis and cell cycle progression were suppressed by
inhibitors of ErbB-1 or ErbB-2 receptors. These results clearly
indicate that ErbB-1 and ErbB-2 activation might be involved
in BTC action in MIN-6 cells, although it is not clear whether
ErbB-1 homodimer or heterodimer of these receptors binds to
BTC.
Signaling pathways mediated by ErbB-1 and ErbB-2 receptors
involve the activation of Ras, MAPK, and the PI3K-activated Akt
pathway, which activates several nuclear proteins, including cyclin
D, a protein required for cell progression from G1 to S phase
[13,38]. We confirmed that cyclin D was translocated from cytosol
to nucleus by BTC treatment (data not shown). Recently, many
studies have shown that various transcription factors are involved
in BTC-induced proliferation [13,19]. One such transcription
factor, CREB, leads to the expression of genes for beta cell
function and survival and plays a role in mediating the effects of
exendin-4, and BTC [20]. As IRS-2, an important mediator of
beta cell proliferation, is one of the CREB-dependent genes [21],
we confirmed that the expression of IRS-2 was upregulated by
BTC treatment, and downregulation of IRS-2 blocked BTC-
induced beta cell proliferation. These results indicate that IRS-2
expression is one mechanism by which BTC enhances beta cell
proliferation, and this is mediated through ErbB-1 and ErbB-2
receptors.
We then asked whether ErbB-1 or ErbB-2 plays a role in the
regeneration of beta cells and remission of diabetes in rAd-BTC-
treated diabetic mice. We found an elevated expression of ErbB-1
and ErbB-2 protein in the pancreatic islets of STZ-induced
diabetic mice or STZ-induced diabetic mice treated with rAd-
BTC as compared with normal mice. Moreover, islet size and the
number of proliferating beta cells in rAd-BTC treated mice was
significantly reduced by treatment with ErbB-1 and ErbB-2
inhibitors. These results suggest that ErbB-1 and ErbB-2
expression in the islets of diabetic mice may facilitate BTC-
induced regeneration of beta cells to compensate for beta cell loss.
Once beta cells are destroyed, ErbB-1 and ErbB-2 expression may
increase, and binding of these receptors to BTC may induce
regeneration of beta cells.
Not only proliferation of pre-existing beta cells but also
differentiation of beta cells from precursor cells residing in the
pancreatic duct cells have been proposed as methods to increase
beta cell mass [39], and BTC is known to have a role in these
processes. A combination of hepatocyte growth factor and BTC-
d4 induced differentiation of pancreatic ductal epithelial cells
into insulin-producing cells, and BTC gene transduction pro-
moted beta cell differentiation from ductal cells [30,40]. Kritzik
et al. observed substantial expression of ErbB receptors in ductal
cells of the regenerating pancreas, especially ErbB-2-positive
cells were more prevalent than ErbB-3- or ErbB-4-positive cells
[41]. Therefore, expression level of ErbBs might be relevant to
ductal cell differentiation, which also contributes to beta cell
regeneration.
Both ErbB-1 and ErbB-2 inhibitors abrogated the remission
effect of BTC in diabetic mice, and the effect was most pro-
nounced with the ErbB-2 inhibitor, which is correlated with the
enhancement of ErbB-2 expression in islets of diabetic mice
treated with rAd-BTC. It is not clear at the present time how the
enhanced islet expression of ErbB-2 relates to beta cell regen-
eration. It was reported that expression of ErbB-2 was significantly
induced in islets adjacent to areas infiltrated by immunocytes
during interferon-c mediated pancreatic regeneration [41].
Therefore, infiltrating immune cells might supply signals that
mediate ErbB-2 induction in the regenerating islets. In addition,
induction of ErbB-1 and ErbB-2 in our study might be part of a
protective response elicited by the islet in response to the islet
damage, but how this works for regeneration of beta cells requires
further investigation.
In summary, our data shows that BTC activated ErbB-1 and
ErbB-2 receptors in beta cells, deliver the signal, and consequently
induce IRS-2 expression, which contributes to beta cell prolifer-
ation. In vivo studies also showed that ErbB-1 and ErbB-2 receptors
are involved in BTC-induced beta cell regeneration at least in part
by inducing beta cell proliferation.
Figure 5. Involvement of ErbB-1 and ErbB-2 receptors in BTC-induced regeneration in vivo. (A) Pancreatic sections were prepared from
untreated NOD.SCID mice (Normal), STZ-induced diabetic NOD.SCID mice (Diabetic), and STZ-induced diabetic NOD.SCID mice treated with rAd-BTC
(rAd-BTC) and stained with anti-ErbB-1 or ErbB-2 antibodies. Photomicrographs of representative islets are shown. (B) STZ-induced diabetic NOD.SCID
mice were treated with rAd-BTC (2610
11 particles). At 3 days after virus injection, mice were treated with vehicle, an ErbB-1 receptor inhibitor
(AG1478) or an ErbB-2 receptor inhibitor (AG825, 500 mg in Captisol, i.p.) twice daily for 10 days. Blood glucose levels were measured. Values are
mean 6 SD of three experiments. (C) Mice were treated as in (B) and pancreatic sections were stained with hematoxylin and eosin. The total islet area
was measured (n=17 islets/group). (D) Mice were treated as in (B) and pancreatic sections were stained with anti-insulin and anti-BrdU antibodies. (E)
Proliferation of insulin-positive cells is shown as the number of BrdU/insulin double-positive cells as a percentage of the total number of insulin-
positive cells (right panel). Scale bars=50 mm, Arrows indicate colocalization. n=15 islets per group.*p,0.05 vs vehicle-treated group.
doi:10.1371/journal.pone.0023894.g005
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Reagents
The sources of various reagents and materials were as follows:
DNase I (Roche Diagnostics, Mannhein, Germany); polyclonal
antibodies against ErbBs, secondary horseradish peroxidase-
conjugated anti-mouse and anti-rabbit antibodies and anti-insulin
antibody were from Santa Cruz Biotechnology Inc. (Santa Cruz,
Ca, USA); anti-phosphotyrosine-20 antibody linked to horseradish
peroxidase was from BD Transduction (Palo Alto, CA, USA);
AG1478 and AG825 were from Calbiochem (La Jolla, CA, USA);
anti-BrdU antibody was from Dako (Carpinteria, CA, USA); and
recombinant mouse BTC was from R&D Systems (Minneapolis,
MN, USA). All other biochemical reagents were from Sigma (St.
Louis, MO, USA) or Invitrogen (Carlsbad, CA, USA).
Cells
MIN-6 cells were routinely cultured in Dulbecco’s modified
Eagle’s medium (DMEM) containing 25 mmol/l glucose supple-
mented with 15% (v/v) fetal bovine serum (FBS), 100 ug/ml
streptomycin, 100 units/ml penicillin streptomycin, and 50 uM b-
mercaptoethanol at 37uCi naC O 2 humidified atmosphere. For
experiments, cells were first incubated for 6 h in medium with 2%
FBS-containing DMEM, and then incubated with various
concentrations of BTC.
Quantification of viable cells
MIN-6 cells were plated in a 96-well plate and incubated in the
absence or presence of BTC. Viable cell number was checked by a
CCK-8 assay kit (Dojindo Lab., Kumamoto, Japan) [42]. Briefly,
10 ml of the CCK-8 solution was added to each well, and the plate
was incubated for 3 h. The absorbance of each well was measured
at 450 nm using a microplate reader (Molecular Devices Corp.,
Menlo Park, USA). The experiment was repeated three times.
3H-Thymidine incorporation assay
For the measurement of DNA synthesis, 1 mCi/ml of
3H-
thymidine (925GBq/mmol, Amersham) was added to each well
for the last 4 h of culture. MIN-6 cells were then harvested with
trypsin/EDTA and transferred on glass fiber filters using a cell
harvester (Skatron Combi, Skatron, Norway).
3H-radioactivity was
measured in a liquid scintillation counter. The experiment was
repeated three times.
Propidium iodide staining and flow cytometric analysis
After treatment with BTC or specific inhibitors, MIN-6 cells
were harvested by treatment with trypsin-EDTA or centrifugation,
respectively, washed twice with PBS, and fixed with ice-cold 70%
ethanol. Cells were pelleted by centrifugation for 5 min at
3,000 rpm at 4uC, and the ethanol supernatants were discarded.
Cells were then resuspended in a propidium iodide solution
(50 mg/ml in PBS) with 50 mg/ml RNase A and incubated in the
dark at room temperature for 20 min. The proportion of cells in S
phase was then analyzed using flow cytometry (FACS Calibur; BD
Transduction). The experiment was repeated five times.
Immunofluorescence staining
MIN-6 cells were plated on 24-well culture plates with
coverslips. After incubation with 0.5 nM of BTC for 24 h, the
cells were washed three times with ice-cold PBS, and fixed in 4%
paraformaldehyde in PBS for 15 min. Pancreata of BrdU-injected
mice were isolated and embedded in paraffin. Pancreatic sections
were deparaffinized in toluene, dehydrated in alcohol, and washed
in water. After antigen unmasking, the slides were permeabilized
in 0.5% Triton X-100, and non-specific protein binding sites were
saturated with 2% BSA in PBS for 1 h. The cell and tissue sections
were incubated with primary antibodies (rabbit anti-insulin, 1:100;
mouse anti-BrdU, 1:100) overnight in a cold room and then
washed three times with ice-cold PBS. Cells were incubated with
fluorescein isothiocyanate-conjugated anti-rabbit or rhodamine-
conjugated anti-mouse secondary antibodies for 30 min. Nuclei
were then fluorescently labeled with DAPI. After washing four
times with ice-cold PBS, the coverslips were mounted on glass
slides with mounting medium. The labeled cells were observed
under a confocal microscope (LSM 700, Carl Zeiss Inc., Oberko-
chen, West Germany) and BrdU-positive and insulin-positive
cells were counted with Image Pro software (Media cybernetics,
Inc., Bethesda, MA, USA). The BrdU labeling index was
calculated as the number of BrdU/insulin double-positive cells
as a percentage of the total number of insulin-positive cells (n=15
islets/group).
Isolation of islets from mice
Islets of Langerhans were isolated from C57BL/6 mice (12
weeks old) by the collagenase digestion technique. About 3 ml of a
collagenase solution (0.8 mg/ml) was injected into the bile duct to
inflate the pancreas. After the pancreas was removed, the tissue
was incubated at 37uC for 5–10 min to complete the digestion.
The islets were then separated by gradient centrifugation at 2000 g
for 10 min on 25, 23, 21.5, and 11.5% Ficoll. Islets at the interface
between the 21.5% and 11.5% Ficoll fractions were collected and
washed with Hank’s balanced salt solution. Healthy islets of
appropriate size were hand-picked under a stereomicroscope. The
dissociated islets were quickly frozen in liquid nitrogen for RNA
isolation.
Immunoprecipitation and immunoblotting
MIN-6 cells were incubated with 0.5 nM BTC for 0, 1, 5, or
15 min, and cell lysates were prepared. For immunoprecipitation,
cell lysates (0.75 mg protein) were precleared by incubation with
30 ml resuspended Protein A/G PLUS beads and 1 mg normal
rabbit IgG on a rotating platform for 1 h at 4uC, followed by
centrifugation at 3,000 rpm for 5 min at 4uC. The supernatants
were incubated with 2 mg anti-ErbB antibodies overnight at 4uC.
Protein A/G PLUS beads were added to the lysate-antibody mix,
followed by incubation for 1 h at 4uC. The beads were washed
four times with lysis buffer. The immunoprecipitates of total cell
lysates were resolved by SDS-PAGE, transferred onto polyviny-
lidenefluoride membranes, blocked for 1 h in 3% BSA in TBS-T
(20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Tween 20) or
3% milk TBS-T, and incubated for 1 h with either anti-phospho-
Tyr (1:5000), anti-ErbB-1 (1:100), anti-ErbB-2 (1:500), anti-ErbB-
3 (1:500), anti-ErbB-4 (1:500), or anti-IRS-2 (1:1000) antibody.
The blots were then incubated with horseradish peroxidase-
conjugated anti-rabbit antibody. Signals were detected by using
the ECL detection system (Pierce, Rockford, IL, USA)
RT-PCR and real-time quantitative PCR
Isolation of total RNA was performed according to the
manufacturer’s recommended protocol for the Tri Reagent
(Invitrogen), and extracted RNA was treated with DNase I and
reverse transcribed to single-strand cDNA using oligo(dT) primer
with PrimeScript
TM RTase (Takara). Appropriate dilutions of
each single-stranded cDNA were prepared for subsequent PCR
amplification by monitoring the GAPDH gene as a quantitative
control. Primer sequences were as follows:
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CGAGCTCTCTCTCTTGA-39 for ErbB-1 (NM_207655; S,
2284–2305; AS, 2357–2335)
59-GCTGCCCGAAACGTGCTA-39 and 59-CCGTGCCAG-
CCCGAA-39 for ErbB-2 (NM_001003817; S, 2541–2559; AS,
2607–2592)
59-AGGCTTGTCTGGATTCTGTGGTT-39 and 59-GGGA-
TCGGGTGCAGAGAGA-39 for ErbB-3 (NM_010153.1; S,
3122–3144 ; AS, 3194–3176)
5-GGAGGCTGCTCAGGACCAA-39 and 59-ACGCAGGC-
TCCACTGTCAT-39 for ErbB-4 (NM_010154.1; S, 706–724 ;
AS, 776–758)
PCR reaction was performed using the following conditions for
ErbBs:
ErbB-1 and ErbB-2: 35 cycles of 1 min at 94uC, 1 min at 60uC
and 1 min at 72uC
ErbB-3 and ErbB-4: 35 cycles of 1 min at 94uC, 1 min at 58uC
and 1 min at 72uC
Samples were analyzed by gel electrophoresis and bands were
revealed by staining gels with ethidium bromide. Real-time
quantitative PCR analysis was performed using SYBR master mix
(Applied Biosystems) using the ABI 7500 Real-time PCR system
according to the protocols provided by the manufacturer (Applied
Biosystems). IRS-2 was amplified using the forward primer 59-
CAGAGCAAGAACCTGACTGGTGTAT and the reverse prim-
er 59-GGCTGTTCGCAATTGAGCTT. The relative mRNA
transcript levels were calculated according to the 2
2DCT method
[43], in which DCT represents the difference in threshold cycle
values between the target mRNA and the cyclophilin internal
control. The experiment was repeated five times.
Transfection with siRNA
The IRS-2 siRNAs were purchased from Dharmacon Research
(Lafeyette, CO, USA) as siGENOME SMART pool. It targeted
four regions of IRS-2 mRNA for interference. The target se-
quences were as follows: IRS-2 #1 GGACGAGUACUUCGCU-
GUA, #2 UCAUGUCCCUUGACGAGUA, #3 GUGAAAGA-
GUGAAGCGCUA, #4 ACUCGGUGG UGGCGCAGAA. A
synthetic Cyclophilin B control pool siRNA was used as a negative
control. MIN-6 cells (1610
5 cells/well) were plated in a 12-well
plate, transfected with 5 pmole of siRNA and lipofectamine
reagent in serum-free medium and incubated for 3 h at 37uCi na
CO2 incubator. Following incubation, the cells were supplied with
growth medium containing 15% fetal bovine serum.
In vivo treatment with rAd-BTC and tyrosine kinase
inhibitors
Recombinant adenoviral vectors expressing BTC (rAd-BTC)
were constructed and produced as previously described [9].
NOD.SCID mice were made hyperglycemic by injection of STZ
(100 mg/kg body weight in citrate buffer, pH 4.5, I.P. twice) and
STZ-induced diabetic mice (blood glucose levels .400 mg/dl)
were injected intravenously with rAd-BTC (2610
11 particles)
through the tail vein [9]. A tyrosine kinase inhibitor, AG1478 or
AG825 (500 mg), in 100 ml of 100 mM of Captisol (Cydex Inc.), an
agent that improves the solubility, stability, and bioavailabilty of
these inhibitors [44], was intraperitoneally injected twice daily for
10 days beginning on the third day after virus injection. Vehicle
alone (100 mM Captisol) was injected as a control. Blood glucose
levels were measured in the tail vein blood twice daily for 10 days
using a glucometer (One Touch; Lifescan, Milpitas, CA, USA). All
experiments using mice were approved by the Institutional Animal
Care and Use Committee at the Rosalind Franklin University of
Medicine and Science and Gachon University Medicine and
Science (LCDI-2008-0021).
Immunohistochemical analyses
Pancreata were fixed in either methacarn (60% methanol v/v,
30% chloroform v/v, and 10% glacial acetic acid v/v) or 10%
buffered formalin overnight and embedded in paraffin, to be used
for hematoxylin-eosin and immunohistochemical staining. Tissue
sections were placed in an oven (95uC for 15 min, 10 mM citrate,
pH 6.0) for antigen retrieval and blocked with blocking solution
(5% goat or horse serum, 1% BSA and 0.05% Tween-20 in PBS).
Tissues were then incubated with goat anti-ErbB-1 or rabbit anti-
ErbB-2, -3, or -4 (Santa Cruz, 1:100). HRP-conjugated goat anti-
rabbit IgG (1:500) or HRP-conjugated horse anti-goat IgG (1:500)
(Chemicon) were used as secondary antibodies, and peroxidase
staining was performed with 3,3-diaminobenzidine (DAB) as a
chromogen (Liquid DAB+ Substrate Chromogen System; Dako).
The size of each islet (n=17 islets/group) was measured in
hematoxylin and eosin-stained slides using a reticule with a phase-
contrast microscope (Carl Zeiss Inc.) and Axio Vision software.
Statistical analysis
Data are presented as means 6 SEM. Statistical analyses were
performed using one-way factorial ANOVA. Pair-wise compari-
sons were evaluated by Duncan’s multiple range test. P,0.05 was
accepted as statistically significant.
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